StockNews.AI
CDTX
StockNews.AI
2 days

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

1. Cidara Therapeutics presents at ISRV meeting in Singapore from Sept 17-20, 2025. 2. Late-breaking abstract details CD388's efficacy in preventing influenza illness. 3. CD388, a long-acting antiviral, aims for universal prevention of influenza. 4. CD388 received FDA's Fast Track Designation in June 2023. 5. Positive results from Phase 2b NAVIGATE trial were announced in June 2025.

4m saved
Insight
Article

FAQ

Why Bullish?

The presentation of positive trial results and promising data could boost investor confidence. Past presentations of successful trials often correlate with stock price increases.

How important is it?

The article highlights key developments that could enhance CDTX’s valuation. The anticipation around the presentations positions CDTX favorably in the market.

Why Short Term?

Immediate interest due to upcoming presentations suggests potential short-term price movements. The significance of the ISRV meeting could drive quick investor reaction.

Related Companies

GILDMRNAPFE
September 03, 2025 08:00 ET  | Source: Cidara Therapeutics, Inc. SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore. Presentation details are summarized below: Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy AdultsPresenter: Rick Bright, Ph.D. Bright Global Health, Cidara TherapeuticsSession: AVG Session 3 Session Date and Time: Wednesday, September 17, 2025, 3:50 – 4:05 p.m. SGT Abstract Title: A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret ModelPresenter: Andreev Konstantin, Ph.D. St. Jude Children’s Research Hospital Session: Parallel Session 2 (Track 1) Session Date and Time: Friday, September 19, 2025, 10:30 a.m. – 12:30 p.m. SGT About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Michael FitzhughLifeSci Communications(628) 234-3889mfitzhugh@lifescicomms.com

Related News